Agilent Biopharma Virtual Symposium - DAY 1

We will also have an exhibition where you can visit various booths to learn more about our latest products and solutions. Our application experts team will be there for you virtually to answer any questions through a convenient chat-box option or via a private video chat.

This is a meeting for you, feel free to get involved, ask questions, make suggestions and be a part of the community.

09:00 a.m. – 10:20 a.m. Practical considerations for Lab Scale Purification of oligonucleotides

• Andrew Coffey (Senior Applications Chemist & Shaun Pritchard, Product Specialist Liquid Phase Separations, Agilent Technologies)

10:20 a.m. – 10:30 a.m. Virtual Exhibition area. Live chat with Agilent at our booths

10:30 a.m. – 11:10 a.m. Tools and Workflows for the purity assessment and impurity characterization/quantification of Oligonucleotides utilizing LC-MS technologies

• Thomas Fechner (BioPharma Market Specialist, Agilent Technologies)

11:10 a.m.– 11:50 a.m.New techniques for assessing drug release from Nanoparticle-based vaccine formulations

• Owain McKenzie (EMEA Dissolution Business Team Manager, Agilent Technologies)

11:50 a.m. – 12:30 p.m. Using LC/MS for characterization of viral vector particles

• Donna Potts (BioPharma Market Specialist, Agilent Technologies)

12:30 p.m. – 01:30 p.m. Virtual Exhibition area. Live chat with Agilent at our booths

01:30 p.m.– 02:10 p.m. Regulatory trends and compliance insights for BioPharma

• Garry Wright (European Laboratory Compliance Specialist, Laboratory Enterprise Division, Agilent Technologies)

02:10 p.m.– 02:45 p.m. Characterization of Adeno-Associated virus by HPLC

• Matthew L. Turner, Ph.D. (Biocolumns Product Manager, Agilent Technologies)

02:45 p.m. – 03:00 p.m. Virtual Exhibition area. Live chat with Agilent at our booths

03:00 p.m. – 03:40 p.m. Minimizing compliance risk for Hardware and Software being used within BioPharma

• Garry Wright (European Laboratory Compliance Specialist, Laboratory Enterprise Division, Agilent Technologies)
• Greg Shaw (Compliance Consultant EMEAI Agilent CrossLab Group, Agilent Technologies)

03:40 p.m. – 04:20 p.m. Simplify removal of common interferences from serum and plasma using a novel Streptavidin based “Ninja” pre-analytical reagent

• Joshua Soldo (Chief Scientific Officer, Ver avas, USA)